Physician profile
Robert Sterling
NPI 1740723253
$8,872.52
in general payments reported to CMS, 2019-2025
28 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,686 · 2022: $1,601 · 2023: $1,804 · 2024: $2,038 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,278 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,278.38 |
| Education | $307.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.36 | 2021-2025 | |
| Janssen Biotech, INC. | $1,119.63 | 2021-2025 | Tremfya, Simponi, Remicade |
| Genzyme Corporation | $717.75 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $714.92 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $643.00 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $594.23 | 2021-2025 | |
| Pfizer INC. | $477.03 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $348.09 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $295.93 | 2022-2025 | Nemluvio, Epsolay |
| Leo Pharma INC. | $277.62 | 2022-2025 | Adbry |
| Incyte Corporation | $236.78 | 2022-2025 | Opzelura |
| Ucb, INC. | $224.68 | 2022-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $195.82 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $183.99 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $178.85 | 2021-2024 | Jublia, Arazlo, Duobrii |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $119.35 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.33 | 2022-2024 | Spevigo |
| Amgen INC. | $107.29 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $100.32 | 2023-2024 | Zoryve |
| Organon LLC | $72.58 | 2024-2025 | Vtama, Hadlima |
| Epi Health, LLC | $69.88 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $51.75 | 2023-2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $47.10 | 2021 | |
| Almirall LLC | $42.31 | 2021 | |
| Genentech USA, INC. | $24.65 | 2024 | Erivedge |
| Dermira, INC. | $22.71 | 2021 | |
| Kyowa Kirin, INC. | $20.23 | 2021 | |
| Biofrontera INC. | $19.34 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.